BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced it will present early safety and efficacy data for ...
BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
(MENAFN- GlobeNewsWire - Nasdaq) BD2 opens its fourth round of Discovery Research funding for bipolar disorder with $18 million available. Washington, D.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Today, ...
Deepcure Inc. has synthesized new 3,4-dihydroquinoxalin-2(1H)-ones acting as bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors. As such, they are described as potentially useful for ...
BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, will present new in vivo data demonstrating its selective BRD4 (BD2) ...
Washington, D.C., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Breakthrough Discoveries for thriving with Bipolar Disorder (BD 2) and CareEvolution announced a new digital platform, BD 2 Connect, designed to ...
Tiumbio Co Ltd. has described bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, fibrosis, diabetes, metabolic syndrome, and renal ...
Bromodomains (BDs), which bind to acetyl lysine in histones and other proteins, have emerged as a class of epigenetic drug targets in cancer. Several inhibitors of the bromodomain and extra-terminal ...
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results